drugset / Trial / NCT00266006

Factor VIIa in Acute Intracerebral Haemorrhage

NCT00266006

Phase 2 Completed 90 enrolled Novo Nordisk A/S
RandomizedFactorialDouble-blindTreatment

Summary

This trial is conducted in Japan. The purpose of this trial is to evaluate the safety and preliminary efficacy of Activated Recombinant Factor VII (NN-007) in patients with acute intracerebral haemorrhage.

Timeline

Start
2006-01
Primary completion
2007-04
Completion
2007-04

Drugs

EvaluationDrugModalityDoseRoute
Subject eptacog alfa (activated) Protein / enzyme biologic